Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004148 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00004148: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00004148 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004148, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of vaccine therapy in treating patients who have unresectable metastatic melanoma. Vaccines may make the body build an immune response to kill tumor cells.
Interventions
- BIOLOGICAL recombinant vaccinia-B7.1 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 1999-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004148
The ClinicalTrials.gov registry entry for NCT00004148 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which recombinant vaccinia-B7.1 vaccine is the first listed.
NCT00004148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004148 about?
NCT00004148 is a clinical study titled "Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma". Phase I trial to study the effectiveness of vaccine therapy in treating patients who have unresectable metastatic melanoma. Vaccines may make the body build an immune response to kill tumor cells.
What is the current status of trial NCT00004148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 1999-10.
What interventions are being tested in trial NCT00004148?
The interventions under investigation include: recombinant vaccinia-B7.1 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004148?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.